Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

Sean Wharton, Melanie Davies, Dror Dicker, Ildiko Lingvay, Ofri Mosenzon, Domenica M. Rubino, Sue D. Pedersen

Research output: Contribution to journalComment/debatepeer-review

9 Scopus citations

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and recommended for weight management in overweight or obesity. Gastrointestinal side effects are well known as the most common adverse effects of these agents and represent a potential barrier for use, particularly at higher doses. Drawing on both published evidence and our collective clinical experience, we aim to guide practitioners through managing these side effects with a view to optimizing therapeutic outcomes with GLP-1RAs.

Original languageEnglish (US)
JournalPostgraduate medicine
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice'. Together they form a unique fingerprint.

Cite this